Drug Prices
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to their own specialty pharmacies, write AHA鈥檚 Mark Howell, director of policy and patient safety, and Bharath Krishnamurthy, director of鈥
A new AHIP 鈥渞eport鈥 suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that specialty pharmacies, many of which insurers conveniently own through their pharmacy benefit manager (PBM) affiliates, provide a lower-cost鈥
A new AHIP 鈥渞eport鈥 suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that specialty pharmacies, many of which insurers conveniently own through their pharmacy benefit manager (PBM) affiliates, provide a lower-cost鈥
Hospitals appreciate the support and resources that Congress have provided throughout the COVID-19 pandemic; however, additional support is needed to keep hospitals strong so they can continue to provide care to patients and communities.
Learn how Mark Cuban is disrupting drug pricing and making waves in the pharmaceutical industry. Find out more about his Cost Plus Drugs company and its collaborations with payers and pharmacists.
The Medicare Payment Advisory Commission today voted to recommend Congress adopt additional site-neutral payment policies for certain outpatient services; reduce add-on payments and adopt other policies to address high Medicare Part B drug costs; and repeal the existing Medicare wage index system鈥
The state of California put up $50 million to have Civica Rx manufacture and distribute low-cost biosimilars for the three most used short- and long-acting insulins.
The Centers for Medicare & Medicaid Services this week released for comment initial guidance implementing a program for Medicare to negotiate prices with drug makers for certain high-cost, single-source drug and biological products beginning in 2026 under the Inflation Reduction Act.
The Centers for Medicare and Medicaid Services (CMS) March 15 announced 27 prescription drugs for which it will lower Part B beneficiary coinsurance, beginning April 1 through June 30, 2023, as required by the Inflation Reduction Act (IRA).
The Centers for Medicare and Medicaid Services (CMS) March 15 announced 27 prescription drugs for which it will lower Part B beneficiary coinsurance, beginning April 1 through June 30, 2023, as required by the Inflation Reduction Act (IRA). This is a table of those drugs.